{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Non+Small+Cell+Lung+Cancer&page=2",
    "query": {
      "condition": "Advanced Squamous Non Small Cell Lung Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Non+Small+Cell+Lung+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T19:10:29.464Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02952989",
      "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Renal Cell",
        "Breast Neoplasms",
        "Urinary Bladder Neoplasm",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Colorectal Neoplasms",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "SGN-2FF",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2017-02-23",
      "completion_date": "2019-06-24",
      "has_results": false,
      "last_update_posted_date": "2019-07-19",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02952989"
    },
    {
      "nct_id": "NCT02784158",
      "title": "An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Lung Cancer",
        "Advanced Malignancies",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ariad Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Orange, California • Detroit, Michigan",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02784158"
    },
    {
      "nct_id": "NCT07503808",
      "title": "A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma",
        "High Grade Serous Ovarian Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Colorectal Cancer",
        "Castration-resistant Prostate Cancer",
        "Non Small Cell Lung Cancer",
        "Endometrium Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "IDE034",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2026-02-24",
      "completion_date": "2027-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 15,
      "location_summary": "Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07503808"
    },
    {
      "nct_id": "NCT03849469",
      "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Triple Negative Breast Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Carcinoma",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced or Metastatic Solid Tumors",
        "Prostate Carcinoma",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Squamous Cell Anal Cancer",
        "Squamous Cell Penile Carcinoma",
        "Squamous Cell Vulvar Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb®22841",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-05-29",
      "completion_date": "2023-02-16",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 28,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03849469"
    },
    {
      "nct_id": "NCT04736173",
      "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Nonsquamous Non Small Cell Lung Cancer",
        "Squamous Non Small Cell Lung Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2021-02-08",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 3,
      "location_summary": "Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Kingwood",
          "state": "Texas"
        },
        {
          "city": "Blacksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04736173"
    },
    {
      "nct_id": "NCT03515629",
      "title": "REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "REGN2810/ipi",
          "type": "DRUG"
        },
        {
          "name": "REGN2810/chemo/ipi",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-07-02",
      "completion_date": "2021-07-29",
      "has_results": true,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03515629"
    },
    {
      "nct_id": "NCT00276588",
      "title": "Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-08-09",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00276588"
    },
    {
      "nct_id": "NCT00090961",
      "title": "S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Cancer",
        "Pulmonary Complications"
      ],
      "interventions": [
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "supervised exercise program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "2004-09",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 60,
      "location_summary": "Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Chanute",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090961"
    },
    {
      "nct_id": "NCT03989115",
      "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "RMC-4630",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Drug: Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2019-07-02",
      "completion_date": "2022-02-08",
      "has_results": true,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03989115"
    },
    {
      "nct_id": "NCT05238883",
      "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Melanoma",
        "Sarcoma",
        "Testicular Germ Cell Tumor",
        "Cervical Cancer",
        "Mesothelioma",
        "Non Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "HFB200301",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HiFiBiO Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-03-10",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-28T19:10:29.464Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238883"
    }
  ]
}